scholarly journals Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

2011 ◽  
Vol 226 (9) ◽  
pp. 2316-2328 ◽  
Author(s):  
Mary E. Irwin ◽  
Kelly L. Mueller ◽  
Natacha Bohin ◽  
Yubin Ge ◽  
Julie L. Boerner
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Lipid Raft ◽  
Kinase Inhibitor ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase

scholarly journals Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer

2019 ◽  
Vol 27 (8) ◽  
pp. 871-877 ◽  
Author(s):  
Xinwen Wang ◽  
Fupeng Zhang ◽  
Xi Yang ◽  
Meiping Xue ◽  
Xiaoli Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Second Generation ◽  
Kinase Inhibitor ◽  
Lung Cancer Cells ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase ◽  
Secreted Phosphoprotein 1

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), afatinib, has been approved for treating EGFR mutant lung cancer patients, but the mechanism of acquired resistance to afatinib has not been well studied. In this study, we established afatinib acquired resistant cell lines. Gene array technology was used to screen changes in gene expression between afatinib-resistant lung cancer cells and parental cells. Our results showed that secreted phosphoprotein 1 (SPP1) was significantly increased in afatinib-resistant lung cancer cells. To study the effect of SPP1 on afatinib resistance, siSPP1 was used to knock down SSP1 in afatinib-resistant lung cancer cells. Then sensitivity to afatinib and invasive ability were studied. We found that knockdown of SPP1 increased sensitivity of lung cancer cells to afatinib and decrease the ability of invasion. Of clinical significance, we found that SSP1 was upregulated in lung cancer tissues compared with adjacent normal tissues, and low level of SSP1 was strongly associated with better overall survival. Our results suggest that SPP1 enhanced the second-generation EGFR TKI resistance in lung cancer, and inhibiting SPP1 might be a therapeutic target to overcome afatinib resistance.

Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro

The Prostate ◽  
2009 ◽  
Vol 69 (14) ◽  
pp. 1529-1537 ◽  
Author(s):  
Claudio Festuccia ◽  
Giovanni Luca Gravina ◽  
Leda Biordi ◽  
Sandra D'Ascenzo ◽  
Vincenza Dolo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Kinase Inhibitor ◽  
Prostate Cancer Cells ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

2006 ◽  
Vol 102 (3) ◽  
pp. 275-282 ◽  
Author(s):  
Monica R. Maiello ◽  
Amelia D’Alessio ◽  
Antonella De Luca ◽  
Adele Carotenuto ◽  
Anna Maria Rachiglio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Kinase Inhibitor ◽  
Intrinsic Resistance ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

2006 ◽  
Vol 207 (2) ◽  
pp. 420-427 ◽  
Author(s):  
Nicola Normanno ◽  
Antonella De Luca ◽  
Monica R. Maiello ◽  
Manuela Campiglio ◽  
Maria Napolitano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Kinase Inhibitor ◽  
Mapk Pathway ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase
Sign in / Sign up

Export Citation Format

Share Document